NCT04779879 - Safety, Tolerability and Pharmacokinetics of Second Generation VIR-7831 Material in Non-hospitalized Participants With Mild to Moderate COVID-19 | Biotech Hunter

Enrollment

354

Participants

Timeline

Start Date

February 18, 2021

Primary Completion Date

August 20, 2021

Study Completion Date

April 6, 2022

Conditions

Covid19

Interventions

BIOLOGICAL

Sotrovimab (Gen1)

Participants will be randomized to receive an IV infusion of Sotrovimab Gen 1 material

BIOLOGICAL

Sotrovimab (Gen2)

Participants will be randomized to receive Sotrovimab Gen2 material by IV infusion or by IM injection

BIOLOGICAL

Sotrovimab (Gen2)

Participants will be randomized to receive Sotrovimab Gen2 material by IV infusion

Trial Locations (31)

10456

Investigative Site, The Bronx

18014

Investigative Site, Granada

20132

Investigative Site, Milan

20850

Investigative Site, Rockville

28031

Investigative Site, Madrid

28040

Investigative Site, Madrid

28223

Investigative Site, Pozuelo de Alarcón

31904

Investigative Site, Columbus

32607

Investigative Site, Gainesville

32803

Investigative Site, Orlando

33016

Investigative Site, Hialeah

33024

Investigative Site, Pembroke Pines

33125

Investigative Site, Miami

33135

Investigative Site, Miami

33155

Investigative Site, Miami

33176

Investigative Site, Miami

33614

Investigative Site, Tampa

34982

Investigative Site, Ft. Pierce

35015

Investigative Site, Daejeon

36207

Investigative Site, Anniston

36312

Investigative Site, Vigo

60190

Investigative Site, Winfield

77090

Investigative Site, Houston

91325

Investigative Site, Northridge

93301

Investigative Site, Bakersfield

N7T 4X3

Investigative Site, Sarnia

M9V 4B4

Investigative Site, Toronto

03010

Investigative Site, Alicante

08006

Investigative Site, Barcelona

08540

Investigative Site, Centelles

08430

Investigative Site, La Roca del Vallès